Colon cancer symptoms in women are similar to those in men, but they can be confused with gynecological issues, like cramping ...

For the past two decades there have been two movements that have taken over men's faces during the month of November.

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...

LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent") (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...

LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and firs ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

For one day each October, downtown Orlando is flooded with pink. Decked out in tutus, wigs, and even pink sneakers, The American Cancer Society’s Making Strides Against Breast Cancer Walk brings ...

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myelomaFirst-in-Human Phase 1 data for allogeneic ...

Cancer, even the word itself, evokes fear. It’s a shadow that looms over nearly everyone as they age, sparking anxious questions: Will I get it? What kind? Will it be caught early enough? While ...

Germany’s growers have started to cut their Christmas trees in anticipation of a tradition that’s around 500 years old.

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...